ORPHA:70573
Small cell lung cancer
Also known as: SCLC
Publications
287,180
100th percentile
Trials
6,611
Interventional, condition-specific
Researchers
1,218
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Small cell lung cancer (SCLC) is a highly aggressive malignant neoplasm, accounting for 10-15% of lung cancer cases, characterized by rapid growth, and early metastasis. SCLC usually manifests as a large hilar mass with bulky mediastinal lymphadenopathy presenting clinically with chest pain, persistent cough, dyspnea, wheezing, hoarseness, hemoptysis, loss of appetite, weight loss, and neurological and endocrine paraneoplastic syndromes. SCLC is primarily reported in elderly people with a history of long-term tobacco exposure.
How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008433
- MeSH:D055752
- OMIM:182280
- UMLS:C0149925
- NCIT:C4917
Additional Mondo synonyms (13)
lung oat cell carcinoma · lung small cell carcinoma · lung small cell neuroendocrine carcinoma · oat cell carcinoma of lung · oat cell carcinoma of the lung · oat cell lung carcinoma · small cell cancer of the lung, somatic · small cell carcinoma of lung · small cell carcinoma of the lung · small cell lung cancer · small cell neuroendocrine carcinoma of lung · small cell neuroendocrine carcinoma of the lung · small-cell cancer of lung
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
287,180 matched papers (202,319 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
6,611 matched on ClinicalTrials.gov (1448 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
287,180
287,180 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
287,180 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
202,319 in the last 10 years · medium confidence · 100th percentile (publications denominator)
Phrase hits: 286,653 · MeSH hits: 1,233
Who's working on it?
1,218
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Liu X12 papers · 2026
Changchun University of Chinese Medicine Jilin Ginseng Academy Changchun China.
Papers in Europe PMC - 02Wang Y8 papers · 2026
Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Papers in Europe PMC - 03Wang J7 papers · 2026
Department of Thoracic Surgery, Peking University People's Hospital, Beijing, 100044, China; Thoracic Oncology Institute, Peking University People's Hospital, Beijing, 100044, China; Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer, Chinese Academy of Medical Sciences, 2021RU002, Peking University People's Hospital, Beijing, 100044, China; Institute of Advanced Clinical Medicine, Peking University, Beijing, 100191, China. Electronic address: jwangmd@pku.edu.cn.
Papers in Europe PMC - 04Zhang J7 papers · 2026
Radiology Department, Ningbo No.2 Hospital, Ningbo, 315010, China.
Papers in Europe PMC - 05Li M6 papers · 2026
Department of Radiotherapy, Third Affiliated Hospital of Kunming Medical University (Yunnan Cancer Hospital, Yunnan Cancer Center), Kunming, 650000 China.
Papers in Europe PMC - 06
- 07Chen Y5 papers · 2026
Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Shaoxing University, Shaoxing, China.
Papers in Europe PMC - 08
- 09Chen J4 papers · 2026
Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, Guangzhou, China.
Papers in Europe PMC - 10Chen Z4 papers · 2026
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
6,611
interventional trials for this specific condition
6,611 interventional trials matched this specific condition name; 1448 currently recruiting in our sample.
Data as of 27 July 2026
6,611 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 100th percentile).
medium confidence · 100th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
6,611 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06525350·NOT YET RECRUITING·A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
Conditions: Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression·Matched via name phrase
- NCT06896422·RECRUITING·Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Conditions: Non-Small Cell Lung Cancer · Chemotherapy · PD1 Antibody · Glutathione·Matched via name phrase
- NCT03769129·RECRUITING·Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
Conditions: Non Small Cell Lung Cancer·Matched via name phrase
- NCT06465329·RECRUITING·A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Conditions: Non-Small Cell Lung Cancer·Matched via name phrase
- NCT03851445·RECRUITING·Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Conditions: Previously Treated Non-Small Cell Lung Cancer·Matched via name phrase
- NCT03742687·RECRUITING·Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Conditions: Stage III Non-small-cell Lung Cancer · Stage IV Non-small Cell Lung Cancer · Radiotherapy Side Effect·Matched via name phrase
- NCT06497530·RECRUITING·Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Conditions: Extensive-Stage Small Cell Lung Cancer·Matched via name phrase
- NCT07720167·NOT YET RECRUITING·Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer·Matched via name phrase
- NCT06198907·NOT YET RECRUITING·Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
Conditions: Non-Small-Cell Lung Cancer·Matched via name phrase
- NCT07376499·NOT YET RECRUITING·Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
Conditions: Small Cell Lung Cancer·Matched via name phrase
- NCT07650357·NOT YET RECRUITING·A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)
Conditions: Advanced Solid Tumor · Non Small Cell Lung Cancer · Pancreatic Carcinoma · Colorectal Cancer·Matched via name phrase
- NCT04210492·RECRUITING·Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Conditions: Non-small Cell Lung Cancer·Matched via name phrase
- NCT07674368·NOT YET RECRUITING·Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
Conditions: ALK Fusion-positive Non-small Cell Lung Cancer·Matched via name phrase
- NCT05815173·RECRUITING·Ladarixin With Sotorasib in Advanced NSCLC
Conditions: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation·Matched via name phrase
- NCT07418879·NOT YET RECRUITING·A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
Conditions: Non-small Cell Lung Cancer · RET Fusion · Pralsetinib·Matched via name phrase
Observational and natural-history studies
1,042 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06418412·RECRUITING·A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Conditions: Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer·Matched via name phrase
- NCT06634199·RECRUITING·Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Conditions: Non-small Cell Lung Cancer Stage III · PDL1 Gene Mutation·Matched via name phrase
- NCT07288632·RECRUITING·Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer
Conditions: Venous Thromboembolism (VTE) · NSCLC (Advanced Non-small Cell Lung Cancer)·Matched via name phrase
- NCT07401615·RECRUITING·Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions
Conditions: Non Small Cell Lung Cancer · Pulmonary Stereotactic Radiotherapy·Matched via name phrase
- NCT07670442·NOT YET RECRUITING·Epigenomic Profiling of Circulating Cell-Free DNA (cfDNA) to Characterize the Dynamic Evolution of Molecular Subtypes in Extensive-Stage Small Cell Lung Cancer During First-Line Chemoimmunotherapy
Conditions: Small Cell Lung Cancer·Matched via name phrase
- NCT07008742·RECRUITING·Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer
Conditions: Oncogene-addicted Non Small Cell Lung Cancer · Early-stage Operable Non Small Cell Lung Cancer · Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer·Matched via name phrase
- NCT02511288·RECRUITING·LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer
Conditions: Carcinoma, Non-Small-Cell Lung·Matched via name phrase
- NCT04510129·RECRUITING·A Multicenter Cancer Biospecimen Collection Study
Conditions: Cancer of Head and Neck · Lung Cancer, Nonsmall Cell · Small-cell Lung Cancer · Urothelial Carcinoma·Matched via name phrase
- NCT06033248·RECRUITING·Using Urine Samples to Identify Lung Cancer
Conditions: Non Small Cell Lung Cancer·Matched via name phrase
- NCT05352035·RECRUITING·Multiomics Tumor Evolution Model of NSCLC
Conditions: Non-small Cell Lung Cancer·Matched via name phrase
- NCT06255197·RECRUITING·Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
Conditions: Lung Cancer · Lung Adenocarcinoma · Lung Squamous Cell Carcinoma · Non Small Cell Lung Cancer·Matched via name phrase
- NCT06361589·RECRUITING·Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients
Conditions: ALK-positive Non-small Cell Lung Cancer · Real World Study·Matched via name phrase
- NCT06934343·RECRUITING·Machine Learning Approaches to Personalized Therapy for Advanced Non-small Cell Lung Cancer With Real-World Data
Conditions: Non-small Cell Lung Cancer·Matched via name phrase
- NCT06883136·ENROLLING BY INVITATION·Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
Conditions: Non-Small Cell Lung Cancer·Matched via name phrase
- NCT07234604·NOT YET RECRUITING·Is 3D Modeling From Non-contrast CT Accurate for Minimally Invasive Lung Segmentectomies ?
Conditions: Lung Cancer · Non-Small Cell Lung Cancer·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Small cell lung cancer" OR "lung oat cell carcinoma" OR "lung small cell carcinoma" OR "lung small cell neuroendocrine carcinoma" OR "oat cell carcinoma of lung" OR "oat cell carcinoma of the lung" OR "oat cell lung carcinoma" OR "small cell cancer of the lung, somatic" OR "small cell cancer of lung, somatic" OR "small cell carcinoma of lung" OR "small cell carcinoma of the lung" OR "small cell neuroendocrine carcinoma of lung" OR "small cell neuroendocrine carcinoma of the lung" OR "small-cell cancer of lung" OR "small-cell cancer of the lung"
MeSH descriptor terms unioned into the query: Small Cell Lung Carcinoma
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Small cell lung cancer" OR "lung oat cell carcinoma" OR "lung small cell carcinoma" OR "lung small cell neuroendocrine carcinoma" OR "oat cell carcinoma of lung" OR "oat cell carcinoma of the lung" OR "oat cell lung carcinoma" OR "small cell cancer of the lung, somatic" OR "small cell cancer of lung, somatic" OR "small cell carcinoma of lung" OR "small cell carcinoma of the lung" OR "small cell neuroendocrine carcinoma of lung" OR "small cell neuroendocrine carcinoma of the lung" OR "small-cell cancer of lung" OR "small-cell cancer of the lung" OR "Small Cell Lung Carcinoma"
Interventional trials matched via: both, phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 6611 interventional · 1042 observational · 41 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: SCLC
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T01:33:39.953Z
